Tag: research

Good news for the unvaccinated

Claus Hancke

November 25, 2021

What is happening in the Danish society?
Denmark is a wonderful country! One must look for a long time for a more tolerant, incorruptible and trusting people!
So far, most Danes can probably agree.

Therefore, we can not help but ask: What is happening in our country right now?
Are we talking about an A-team and a B-team? The vaccinated and the UN-vaccinated? Yes, according to the Danish Prime Minister, we are!
It is disrespectful, and we must go far back in history to see such state-run disgrace of a minority.
And is it at all true that the unvaccinated are a danger and “live life dangerously”? Let’s look at the facts.

We can ourselves
Every day in our lives where we are symptom-free (healthy), it is not due to the absence of viruses or bacteria, but to the presence of an active, balanced immune system that does exactly what it is designed for.
– And which no vaccine can replace.

When health professionalism became politics
Lack of knowledge and misinformation of the population has led to an unjustified fear of viruses and an equally unjustified one-sided focus on vaccines. But worse still, it has created a disunion in the population.

That politicians, agencies, government officials, health professionals, and the general public have been convinced that infection is the same as disease is spin and politics and not health science.

A high infection rate does not matter if there are no patients. When 1,000 persons are infected without anyone dying, it means that 1,000 persons gain natural, strong immunity.
So when the Danish National Board of Health now reduces the duration of natural immunity from 12 to 6 months in the corona passport, then that policy is contrary to science.

If we observe the total mortality in Denmark over the past 20 years, we can state that mortality had not increased in 2020, when we had an epidemic at full strength, but no vaccines.
Covid-19 has thus not increased mortality in Denmark.

Furthermore, we can state that mortality has not decreased in 2021 (January to October), where we have vaccinated 80% of the population and 90% of the risk groups.
The vaccines have thus not reduced mortality in Denmark.

Even the number of infections today is much higher than it was the same day a year ago, although fewer are being tested now.
Thus, the vaccines have not reduced the number of infections either.

Why do some people’s immune system fail?
A groundbreaking study from the University of Copenhagen (KU) showed that vitamin D is necessary for our ability to survive infections in the normal way. The findings of the study were evaluated by the University of Copenhagen and determined to be so important that “a number of immunology books must be rewritten“.

Vitamin D in sufficient amounts is crucial for activating the immune system in infections, and “switching it off” again afterwards, so that the immune response is normalized.
The study explains the mechanism that has been sought in 50-60 years of vitamin D research.
The informed reader of the previous newsletters is well aware that in the absence of certain micronutrients, the immune system will fail.

Such a deficiency can not be remedied by simply taking the doses that are currently recommended here in Denmark. These are often too low because they do not take into account poor diet, improper preparation of food, stress, smoking, medication, etc., which leads to a greater need for these nutrients.
With a healthy lifestyle and a sufficient intake of the vitamins and minerals that are crucial for the immune system to function as it should, virtually no virus will be generally dangerous to the population in countries with Danish living standards.

Is vaccine our only salvation?
As the vaccine does not prevent infection or transmission, but should only inhibit serious illness in the vaccinated person, it is inconceivable that one wants to vaccinate healthy children who do not risk serious illness. The risk of vaccine side effects and death will here be far greater than the risk of the disease that the vaccine should protect against. This is contrary to The Hippocratic Oath.

Vaccines and only vaccines have been heavily targeted. Not a word about natural, effective, inexpensive and side-effect-free prevention and treatment.
It is like a three-legged stool, where the two legs have been removed, namely prevention and treatment.
Such a one-legged stool will never be able to stand alone.

It therefore surprises us that information about the things that can actually prevent and treat serious illness is not disseminated to the population through the official channels, but on the contrary is censored in a fog of misinformation.

We find it responsibility incurring not to inform about this.

Natural immunity – our main defense
We hear again and again the same experts on TV and in other media repeating that our immunity decreases at the same rate as the amount of antibodies in the blood, both after vaccination and after natural immunity after a viral infection. But this is wrong. A scientifically incorrect assumption. And a misunderstanding. With natural immunity, the amount of antibodies decreases naturally, after a viral infection. It should actually drop.

The wise body
The body is energy efficient and does not use energy and space to maintain high levels of antibodies to a virus it has just fought or the thousands of virus types we are constantly exposed to.
Once the virus has been defeated, the body turns down the flame so that it can again use energy on other processes. And it can do so calmly, because with the infection the natural, strong and often lifelong immunity is built up.
If, after battling the infection, the body continues to maintain high levels of antibodies in the blood for months and years, it is equivalent to a boxer who has just knocked out his opponent in the boxing ring continuing to walk with the parades up for months. That does not make sense.

The important memory cells
In the event of a viral infection, there is an activation of e.g. memory cells, which are coded to be able to recognize the virus they have just been in contact with, so that they can reactivate antibodies again very quickly at later encounters with the virus.

Unlike vaccine immunity, natural immunity is longer lasting, more broad-spectrum and thus more effective against mutations.

The continuous updating of the cells’ memory by natural immunity after infection makes the immune system stronger after each update. This ongoing update does not occur to the same extent with vaccine immunity, where one instead has to revaccinate.

This has just been demonstrated in a new study from August 2021 from Rockefeller University that specifically examines Pfizer’s and Moderna’s mRNA vaccines against natural immunity and has been confirmed by previous studies.

Updated memory cells can quickly activate an immune response adapted to the inevitable re-infections.
The reaction is rapid and the virus is therefore killed before it has time to multiply in an amount that triggers disease symptoms.
This means that we do not detect these recurrent re-infections. In other words, we are symptom-free and healthy, even though from time to time there is a disease virus in the body, and if we are tested for re-infection, it will be possible to measure the virus, and we are thus “infected”, ie. have a positive test. But we are neither sick nor particularly contagious.
Infection rates as a disease indicator are therefore a wrong strategy.

If there was a pandemic with a generally dangerous disease with high mortality (such as Ebola), and there was an effective and proven safe vaccine, then we would all be vaccinated, right?
But something lags. For none of these things are the case.

And it does not increase confidence in authorities, experts and the health system that there can be no calm, open and uncensored debate on these things.

Take care of yourself and others.

Kim Varming, Chief Physician and Clinical Immunologist,
Claus Hancke, Specialist in General Medicine and
Michael Schultz, Physiotherapist and Business Lawyer

Note: This post has in a slightly different form been published as a column in media in the northern part of Jutland 15/11.

Refs:

https://www.dr.dk/nyheder/viden/kroppen/klar-paa-et-tredje-stik-derfor-kan-du-forvente-blive-vaccineret-igen
https://www.nature.com/articles/s41586-021-03647-4
https://www.washingtonpost.com/outlook/2021/09/15/natural-immunity-vaccine-mandate/
https://sundhedspolitisktidsskrift.dk/nyheder/3702-coronabloggen-reinfektion-med-covid-19-hvad-ved-vi.html
https://www.washingtonpost.com/outlook/2021/09/15/natural-immunity-vaccine-mandate/
https://pubmed.ncbi.nlm.nih.gov/34100029/
https://pubmed.ncbi.nlm.nih.gov/33296701/
https://www.cell.com/cell/pdf/S0092-8674(20)31008-4.pdf?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867420310084%3Fshowall%3Dtrue
https://www.nature.com/articles/s41586-021-03647-4
https://pubmed.ncbi.nlm.nih.gov/34100029/
https://www.biorxiv.org/content/10.1101/2021.07.29.454333v1
https://www.medrxiv.org/content/10.1101/2021.08.24.21262415v1
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253687/
https://pubmed.ncbi.nlm.nih.gov/33296701/
https://nyheder.tv2.dk/samfund/2021-05-18-vaccine-og-infektion-giver-immunitet-i-otte-maaneder-oplyser-styrelse
https://www.biorxiv.org/content/10.1101/2021.07.29.454333v2
og https://pubmed.ncbi.nlm.nih.gov/34619745/
https://www.rockefeller.edu/news/30919-natural-infection-versus-vaccination-differences-in-covid-antibody-responses-emerge/
https://nyheder.tv2.dk/2020-07-13-antistoffer-mod-coronavirus-kan-vaere-vaek-allerede-efter-faa-maaneder-viser-nyt-studie
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247032/
https://pubmed.ncbi.nlm.nih.gov/33298562/
https://www.nature.com/articles/ni.1851
https://nyheder.ku.dk/alle_nyheder/2010/2010.3/dvitamin/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775232/
https://www.washingtonpost.com/outlook/2021/09/15/natural-immunity-vaccine-mandate/
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3631261
https://www.cell.com/cell/pdf/S0092-8674(20)31008-4.pdf?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867420310084%3Fshowall%3Dtrue
https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty
https://pubmed.ncbi.nlm.nih.gov/32599103/

Vitamin C Soothes Pain from Osteoarthritis in 14 days

Admin

July 6, 2003

Vitamin C soothes pain from osteoarthritis in 14 days. That is the conclusion of a Danish scientific study recently published in the Danish medical magazine, Ugeskrift for Laeger.

133 patients with osteoarthritis of the hip joint and knee joint were treated with one gram of vitamin C or placebo twice daily for 14 days. In those who got vitamin C there was clearly better pain relief than in the other group.

The study was made because many people have said that vitamin C has helped with their osteoarthritis.

“Our study, which have been carried out to the highest scientific standard, have shown that vitamin C reduces the pain of osteoarthritis of the hip or knee joint within 14 days,” says Niels Hertz, specialist in general medicine.

“This effect was statistically exceptionally safe and led to very clear improvements in the functioning of those with arthritis. The magnitude of the effect is equivalent to half what you normally find with arthritis pills (NSAIDs), but unlike these, the treatment with vitamin C is free of side effects and can be tolerated indefinitely.

The finding is extra interesting because other studies have shown that people with arthritis who get a lot of vitamin C do not worsen as much over time as those who get ordinary Danish average amounts. This was found a few years ago in the famous American Framingham study, a result that attracted attention at the time.

In other words, one can imagine that vitamin C not only relieves the pain of osteoarthritis, but also counteracts aggravation of arthritis!

There are many examples of this happening. A retired nurse, I know, meant for approx. 10 years ago that she could no longer avoid a hip operation. She was in so much pain. Then she started taking vitamin C and today she is still not operated on. I see her regularly on the street, without a cane and in a good mood.

Every twentieth Dane receives less than 30 mg of vitamin C a day, and very few come close to the American averages from Framingham. This is highly unfortunate for public health.

Several of the world’s leading experts in vitamin C believe that the recommended daily allowances (RDA) should be significantly increased.

Vitamin C is, in my opinion, a fantastically exciting vitamin, which most likely has several other positive surprises in it. We are far from finished exploring it, ”concludes Niels Hertz.

By: Vitality Council

Reference:
Jensen, Niels H.P. Hertz, Ugeskr Laeger 2003;165:2563-6.

www.dadlnet.dk
www.iom.dk

Nutrient Research References

Admin

A collection of good nutrient references from before 1999.

Links to the different categories:

Antioxidants in general, Research references

Admin

January 1999

1. Abbott RA, Cox M, Markus H, Tomkins A. Diet, body size and micronutrient status in Parkinson’s disease. Eur J Clin Nutr 46:879-84, 1992.
2. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993; 90: 7915-22.
3. Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci. USA 1995; 92: 5258-65.
4. Azen SP, Qian D, Mack W, et al. Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering. Circulation 94;10:2369-72, 1996.
5. Bhat KS. Nutritional status of thiamine, riboflavin and pyridoxine in cataract patients. Nutr Rep Int 363:685-92, 1987.
6. Boers GH. Hyperhomocysteinaemia: A newly recognized risk factor for vascular disease. Neth J Med 45:1:34-41, 1994.
7. Boniton-Kopp C, Coudray C, Berr C, et al. Combined effects of lipid peroxidation and antioxidant status on carotid atherosclerosis in a population aged 59-71 y: The Eva study. Am J Clin Nutr 65:121-7, 1997.
8. Brattström L. Vitamins as homocysteine-lowering agents: A mini review. Presentation at the American Institute of Nutrition Colloquium, April 13, 1995, Atlanta, Georgia; Brattström L. Vitamins as homocysteine-lowering agents. J Nutr 126:4 Suppl:1276S-1280S, 1996.
9. Calzada C, Bruckdorfer K, Rice-Evans C. The influence of antioxidant nutrients on platelet function in healthy volunteers. Atherosclerosis 128;1: 97-105, 1997.
10. Cerhan JR, Wallace RB, Folsom AR. Antioxidant intake and risk of Parkinson’s Disease in older women. Am J Epidemiol 139;11:S65, 1994.
11. De Lorgeril , Boissonnat P, Salen P, et al. The beneficial effect of dietary antioxidant supplementation on platelet aggregation and cyclosporine treatment in heart transplant recipients. Transplantation 58:193-4, 1994.
12. De Rijk MC et al. Dietary antioxidants and Parkinson disease: The Rotterdam study. Arch Neurology 54:762-5, 1997.
13. Ely J. Crary, Smyrna, Georgia, USA – quoted in Zarrow S. Keep your eyes young and sharp. Prevention March, 1985, pp. 74-80; Crary E. Antioxidant treatment of macular degeneration of the aging and macularedema in diabetic retinopathy. South Med J 80 no. 9, supple 3:38, 1987.
14. Fahn S. An open trial of high-dosage antioxidants in early Parkinson’s disease. Am J Clin Nutr 53:380S-1S, 1991.
15. Gartside PS, Glueck CJ. Relationship of dietary intake to hospital admission for coronary heart and vascular disease: The NHANES II National Probability Study. J Am Coll Nutr 12:6:5676-84, 1993.
16. Ghosh S, et al. Dietary intake and plasma levels of antioxidant vitamins in health and disease: A hospital-based case-control study. J Nutr Environ Med 5:235-42, 1995.
17. Grimes JD et al. Prevention of progression of Parkinson’s disease with antioxidative therapy. Prog Neuropsychopharmacol Biol Psychiatry 122-3:165-72, 1988.
18. Hankinson S, Stampfer M, Seddon J, et al. Nutrient intake and cataract extraction in women: A prospective study. BMJ 305: 335-9, 1992.
19. Heliovaara M, Knekt P, Aho K, et al. Serum antioxidants and risk of rheumatoid arthritis. Ann Rheum Dis 53: 51-3, 1994.
20. Hodis HN, Mack WJ, LaBree L, et al. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA 273;23:1849-54, 1995.
21. Ince S. Vitamin Supplements may help delay onset of AIDS. Medical Tribune September 9, p.18, 1993.
22. Jacques PF, Chylack LT Jr, McGandy RB, Hartz SC. Antioxidant status in persons with and without senile cataract. Arch Ophthalmol 106:3:337-40, 1988.
23. Jacques PF, Chylack LT Jr. Epidemiologic evidence of a role for the antioxidant vitamins and carotenoids in cataract prevention. Am J Clin Nutr 53: 352S-5S, 1991.
24. Jacques PH et al. Vitamin intake and senile cataract. J Am Coll Nutr 6:5:435, 1987.
25. Jain VK, Chandra RK. Does nutritional deficiency predispose to Acquired Immune Deficiency Syndrome (AIDS)? Nutr Res 4:537-43, 1984.
26. Jariwalla RJ. Micro-nutrient imbalance in HIV infection and AIDS: Relevance to pathogenesis and therapy. J Nutr Environ Med 5:297-306, 1995.
27. Knekt P, Reunanen A, Jarvinen R, et al. Antioxidant vitamin intake and coronary mortality in an longitudinal population study. Am JEpidemiol 139:1180-9, 1994.
28. Knekt P, Heliovaara M, Rissanan A, et al. Serum antioxidant vitamins and risk of cataract. BMJ 305:1392-4, 1992.
29. Kritchevsky SB, Shimakawa T, Tell GS, et al. Dietary antioxidants and carotid artery wall thickness: The ARIC study. Circulation 92:8:2142-50, 1995.
30. Manson JE, Stampfer MJ, Willett WC, et al. A prospective study of antioxidant vitamins and incidence of coronary heart disease in women. Abstract. J Am Coll Nutr 11:5:633, 1992.
31. Mares-Perlman J, Klein R, Klein B, et al. Relationship between age-related maculopathy and intake of vitamin and mineral supplements. Invest Ophthalmol Vis Sci 34:1133, 1993.
32. McAlindon TE, Jacques P, Zhang Y, et al. Do antioxidant micronutrients protect against the development and progression of knee osteoarthritis? Arthritis Rheum 39(4): 648-56,1996.
33. Mastroiacovo P et al. Antioxidant Vitamins and Immunodeficiency. Int J Vitam Nutr Res 66:141-5, 1996.
34. Mooradian AD et al. Selected Vitamin and Mineral in Diabetes. Diabetes Care 17; 464-79, 1994.
35. Newsome D et al. The trace element and antioxidant economy of the human macula: Can dietary supplementation influence the course of macular degeneration? J Am Coll Nutr 10:5:536, 1991.
36. Olson RJ. Supplemental dietary antioxidant vitamins and minerals in patients with macular degeneration. J Am Coll Nutr 10:5:550, 1991.
37. Olszewski AJ et al. Reduction of plasma lipid and homocysteine levels by pyridoxine, folate, cobalamin, choline, riboflavin, and troxerutin in atherosclerosis. Atherosclerosis 75:1:1-6, 1989.
38. Pories WJ, Henzel JH, Hennessen JA. Proc U of Missouri First Annual Conference on Trace Substances in the Environment and Health 1968:114, 1967.
39. Rath M, Pauling L. A unified theory of human cardiovascular disease leading the way to the abolition of this disease as a cause for human mortality. J Orthomol Med 7:1:5-15, 1992.
40. Singh R, Niaz M, Bishnol J, et al. Diet, antioxidant vitamins, oxidative stress, and risk of coronary artery disease. Acta Cardiol 49:5:453-67, 1994.
41. Singh RB, Ghosh S, Niaz MA, et al. Dietary intake, plasma levels of antioxidant vitamins and oxidative stress in relation to coronary artery disease in elderly subjects. Am J Cardiol 76:1233-8, 1995.
42. Singh RB, Niaz MA, Ghosh S, et al. Dietary intake and plasma levels of antioxidant vitamins in health and disease: A hospital-based case-control study. J Nutr Environ Med 5:235-42, 1995.
43. Singal PK, Kapur N, Dhillon KS et al. Role of free radicals in catecholamine induced cardiomyopathy. Can J Physiol Pharmacol 60:1390, 1982.
44. Snodderly DM. Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. Am J Clin Nutr 62:suppl:1448S-61S, 1995.
45. Steinberg D.Antioxidants in the prevention of human Artherosclerosis. Circulation 85; 6; 2338-2344, 1992.
46. Tang A, Graham N, Kirby A, et al. Dietary micronutrient intake and the risk of progression to Acquired Immunodeficiency Syndrome (AIDS) in Human Immunodeficiency Virus Type 1 (HIV-1) infected homosexual men. Am J Epidemiol 138: 937-51, 1993.
47. Tang AM, Graham NM, Saah AJ. Effects of Micronutrient Intake on Survival in Human immunodeficiency virus type 1 Infection. Am J Epidemiol 143:1244-56, 1996.
48. Tavani A et al. Food and nutrient intake and risk of cataract. Ann Epidemiol 6:41-6, 1996.
49. Tolonen, Matti: Fria radikaler och antioxidantia i biologi och medicin. Vitaminers og spormineralers betydning for velfærdssygdomme. (Significance of vitamins and traceminerals in disease), Rigshospitalets Symposium, Pharma Nord Research, 1988 (in Danish/Swedish).
50. Vitale S, West S, Hallfrish H, et al. Plasma antioxidants and risk of cortical and nuclear cataract. Epidemiology 4:195-203, 1993.
Ward RJ et al. Reduced antioxidant status in patients with chronic alcoholic myopathy. Biochem Soc Trans 16:581, 1988.
51. Ward RJ, Peters TJ. The antioxidant status of patients with either alcohol-induced liver damage or myopathy. Alcohol Alcohol 27;4:359-65, 1992.
52. Weisberger JH. Nutritional approach to cancer prevention with emphasis on vitamins, antioxidants, and carotenoids. Am J Clin Nutr 1995; 53: 226s.
53. West S, Vitale S, Hallfrisch J, et al. Are antioxidants or supplements protective for age-related macular degeneration? Arch Ophthalmol 112:222-7, 1994.
54. Woodside J et al. The effects of vitamin supplementation on cardiovascular risk. J Inherit Metabol Dis 19:Suppl 1:26/P51, 1996.

– See also betacarotene, Vitamin B6, Vitamin C, Vitamin E, Coenzyme Q10, Selenium and Zinc.

 

Sources:
Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.

Vitamin A, Betacarotene, Research references

Admin

January 1999

1. Band P.R. et al. Treatment of Benign Breast Disease with Vitamin A. Prev Med 549-54, 1984.
2. Bendich A. Symposium conclusions: Biological actions of carotenoids. J Nutr 119: 112-5, 1989.
3. Bichler KH et al. Influence of vitamin A deficiency on the excretion of uromucoid and other substances in the urine of rats. Clin Nephrol 20:32-9, 1983.
4. Branowitz SA, Starrett B, Brookner AR. Carotene deficiency in HIV patients. AIDS 10; (1):115, 1996.
5. Burton GW, Ingold KU. Beta-carotene. An unusual type of lipid antioxidant. Scicnce 224: 569-573, 1984.
6. Cheraskin E, Ringsdorf WM, Medford FH. The ‘ideal’ daily vitamin A intake. Int J Vit Nutr Res 46: 11-13, 1976.
7. Chole Q. Vitamin A in the cochlea. Arch Otorhinolaryngol 124:379-82, 1978.
8. Comstock GW et al. Serum concentrations of alpha-tocopherol, beta-carotene, and retinol preceding the diagnosis of rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 56: 323-5, 1997.
9. Connett JE, Kuller KH, Kjelsberg MO et al. Relationship between carotenoids and cancer. Cancer 64: 126-134, 1989.
10. Coutsoudis A, Bobat R, Coovadia H. The effects of vitamin-A supplementation on the morbidity of children born to HIV-infected women. Am J Public Health 85; (8):1076-81, 1995.
11. Delmas-Beauvieux M-C, Peuchant E, Couchouron A, et al. The enzymatic antioxidant system in blood and glutathione status in human immunodeficiency virus (HIV)-infected patients: Effects of supplementation with selenium or carotene. Am J Clin Nutr 64: 101-7, 1996.
12. DiMascio P, Murphy ME, Sies H. Antioxidant defense systems the role of carotenoids, tocopherols and thiols. Am J Clin Nutr 53: 194S-200S, 1991.
13. Eldred GE. Vitamins A and E in RPE lipofuscin formation and implications for age-related macular degeneration. Prog Clin Biol Res 314: 113-29, 1989.
14. Ferreira R et al. Antioxidant action of vitamins A and E in patients submitted to coronary bypass surgery. Vasc Surg 25: 191-195, 1991.
15. Gaby SK, Singh VN. Vitamin intake and health: A scientific review. New York: Marcel Dekker. p 29-57, 1991.
16. Gershoff SN, McGandy RB. The effects of vitamin A-deficient diets containing lactose in producing bladder calculi and tumors in rats. Am J Clin Nutr 34: 483, 1981.
17. Goodman DS. Vitamin A and retinoids in heath and disease. N Eng J Med 310: 1023-1031, 1984.
18. Hayes KC. Retinal degeneration in monkeys induced by deficiencies of vitamin E or A. Invest Ophthalmol Vis Sci 13:7:499-510, 1974.
19. Honkanen V et al. Vitamins A and E, retinol binding protein and zinc in rheumatoid arthritis. Clin Exp Rheumatol 7: 465-9, 1989.
20. Honkanen VEA et al. Serum cholesterol and vitamins A and E in juvenile chronic arthritis. Clin Exp Rheumatol 8: 187-91, 1990.
21. Liao CH, Erdman JW, Johnston PV. Dietary vitamin A deficiency and the immune system in a murine model of systemic lupus erythematosus. Nutr Res 16: 279-92, 1996.
22. Lohle E. The influence of chronic vitamin A deficiency on human and animal ears. Arch Otorhinolaryngol 234:167-73, 1982.
23. Mckeown LA. Beta carotene lifts CD4 counts. Study reported in Medical Tribune Feb. 25, p. 1. 1993.
24. Mobarhan S, Bowen P, Andersen B et al. Effects of beta-carotene repletion on beta-carotene absorption, lipid peroxidation, and neutrophil superoxide formation in young men. Nutr Cancer 14: 195-206, 1990.
25. Newbold PCH. Beta-carotene in the treatment of discoid lupus erythematosus. Br J Dermatol 95: 100-1, 1976.
26. Olson JA. Vitamin A. In: Present knowledge in nutrition. 7th edn. Washington DC: Intemational Life Sciences Press. p 109-119, 1996.
27. Oson JA. Provitamin A function of carotenoids. Thc conversion of B-carotene to Vitamin A. J Nutr 119: 105-108, 1989.
28. Paganini-Hill A, Chao A, Ross RK et al. Vitamin A, beta carotene and the risk of cancer. A prospective study. J Natl Cancer Inst 79: 443-448, 1987.
29. Palgi A. Association between dietary changes and morality rates; Israel 1949 to 1977; a trend-free regression model. Am J Clin Nutr 34: 1569-1583, 1981.
30. Prince MR, Frisoli JK. Beta-carotene accumulation in serum and skin. Am J Clin Nutr 1993; 57: 175-181, 1993.
31. Pryor WA. The antioxidant nutrients and disease prevention what do we know and what do we need to find out? Am J Clin Nutr 53: 391S-393S, 1991.
32. Riemersma RA, Wood DA, MacIntyre CCH, et al. Risk of angina pectoris and plasma concentrations of vitamins A, C and E and carotene. Lancet 337:1-5, 1991.
33. Romeo G. The therapeutic effect of vitamins A and E in neurosensory hearing loss. Acta Vitaminol Enzymol 7 Suppl:85-92, 1985.
34. Sahyoun NR et al. Carotenoids, vitamins C and E, and mortality in an elderly population. Am J Epidemiol 144:5:501-11, 1996.
35. Sappey C et al. Vitamin, Trace element and Peroxide status in HIV seropositive patients: Asymptomatic patients present a severe Carotene Deficiency. Clin Clim Acta 230:35-42, 1994.
36. Semba R, Graham N, Caiaffa W, et al. Increased Mortality associated with Vitamin A Deficiency during Human Immunodeficiency Virus type 1 infection. Arch Intern Med 153:2149-54, 1993.
37. Semba RD, Park S, Royal W, Griffin DE. Vitamin A deficiency and T-cell subpopulation in HIV-infected adults. Nutr Res 16:915-23, 1996.
38. Sommer A., West, KP. The duration of the effect of vitamin A supplementation. Am J Public Health 1997; 87: 467, 1997.
39. Salonen JT. Risk of cancer in relation to serum concentrations of selenium and vitamins A and E: matched case-control analysis of prospective data. Br Mcd J 1985, 290: 417-420, 1985.
40. Schauss AG. Beta-carotene and the incidence of lung cancer in Finnish male smokers. A critique. Q Rev Natural Med 191-195, 1994.
41. Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. JAMA 272:1413-20, 1994.
42. Stahelin HB, Gey KB, Eichholzer M et al. Beta-carotene and cancer prevention. The Basel Study. Am J Clin Nutr 53: 265S-269S, 1991.
43. Street DA et al. Serum antioxidants and myocardial infarction: Are low levels of carotenoids and alpha-tocopherol risk factors for myocardial infarction? Circulation 90;3:1154-61, 1994.
44. Tang AM et al. Association between Serum Vitamin A and E levels and HIV-1 disease progression. AIDS 11:613-20, 1997.
45. Underwood BA. Was the ‘anti-infective’ vitamin misnamed? Nutr Rev 52: 140-143, 1994.
46. Vitale S et al. Plasma vitamin C, E and beta carotene levels and risk of cataract. Invest Ophthalmol Vis Sci 32:723, 1991.
47. Weisburger J. Nutritional approach to cancer prevention with emphasis on vitamins, antioxidants, and carotenoids. Am J Clin Nutr 53: S226-237, 1991.
48. Weisberger JH. Nutritional approach to cancer prevention with emphasis on vitamins, antioxidants, and carotenoids. Am J Clin Nutr 1995; 53: 226s.
49. Werler MA, Lammer EJ, Mitchell AA. Teratogenicity of high vitamin A intake. Letter. N Eng J Med 334: 1195, 1995.
50. White WS, Kim Cl, Kalkwarf HJ et al. Ultraviolet light-induced reduction in plasma carotenoid levels. Am J Clin Nutr 47: 879-883, 1988.
51. Willette W. Nutritional epidemiology. New York: Oxford University Press. p 292-310, 1990.
52. Ziegler RG. Vegetables, fruits and carotenoids and the risk of cancer. Am J Clin Nutr 53: 251S-259S, 1991.

Sources
Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.

Vitamin B1, Research references

Admin

January 1999

1. Allison JR. The relation of hydrochloric acid and vitamin B complex deficiency in certain skin diseases. South Med J 38: 235-241, 1945.
2. Bendich A, Cohen M. Nutrition and Immunology. New York: Alan R. Liss. p 101-123, 1988.
3. Butterworth RF et al. Thiamin deficiency in AIDS. Lancet 338:1086, 1991.
4. Cheraskin E, Ringsdorf WM Jr, Setyaadmadja AT et al. Thiamin consumption and cardiovascular complaints. J Am Geriatrics Soc 15: 1074-1079, 1967.
5. Cheraskin E, Ringsdorf WM Jr, Setyaadmadja AT et al. Carbohydrate consumption and cardiovascular complaints. Angiology 18: 224-230, 1967.
6. Cheraskin E, Ringsdorf WM Jr, Medford FH et al. The ‘ideal’ daily vitamin B, intake. J Oral Med 33: 77-79, 1978.
7. Cheraskin E, Ringsdorf WM Jr. How much refined carbohydrate should we eat? Am Lab 6: 31-35, 1974.
8. Cummings F, Briggs M, Briggs, M. Vitamins in human biology and medicine. Boca Raton, FL: CRC Press. 1981.
9. Iber FL, Blass JP, Brin M et al. Thiamin in the elderly-relation to alcoholism and to neurological degenerative disease. Am J Clin Nutr 6: 1067-1082, 1982.
10. Lonsdale DA. Nutritionist’s guide to the clinical use of vitamin B1. Tacoma, WA: Life Sciences Press. p 1-209, 1987.
11. Lonsdale D. Red cell transketolase studies in a private practice specializing in nutritional correction. J Am Coll Nutr 7: 61-68, 1988.
12. Rindi, G. Thiamin. In: Present knowledge in nutrition. 7th edn. Washington DC: International Life Sciences Press. p 160-166, 1996.
13. Ropert R. Utilisation de la Vitamine B1 fortes doses dans le traitement de divers syndromes douloureux facio-céphaliques. Sem Hôp 4:508-9, 1958 (in French).
14. Shils ME, Young VR. Modern nutrition in health and disease. 7th edn. Philadelphia: Lea and Febiger. p 358, 1988.

 

Sources
Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.

Vitamin B2, research references

Admin

January 1999

1. Belko AZ, Obarzanek E, Kalkwarf HJ et al. Effects of exercise on riboflavin requirements of young women. Am J Clin Nutr 37: 509-517, 1983.
2. Belko AZ, Obazanek E, Roach R et al. Effects of aerobic exercise and weight loss on riboflavin requirements of moderately obese, marginally deficient young women. Am J Clin Nutr 40: 553-561, 1984.
3. Belko AZ, Meredith MP, Kalkwarf HJ et al. Effects of exercise on riboflavin requirements. Biological validation in weight reducing women. Am J Clin Nutr 41: 270-277, 1985.
4. Bendich A, Cohen M. Nutrition and Immunology. New York: Alan R. Liss. p. 114, 1988.
5. Beutler E. Glutathione reductase. Stimulation in normal subjects by riboflavin supplementation. Science 165: 614-615, 1969.
6. Goodwin JS, Garry PJ. Relationship between megadose vitamin supplementation and immunological function in a healthy elderly population. Clin Exp Immunol 51: 647-653, 1983.
7. Joint, FAO/WHO Expert Group. Riboflavin. WHO Technical Report Series No. 362. p. 86, 1967.
8. Prchal JT, Conrad ME, Skalka HW. Association of presenile cataracts with heterozygosity for glactosaemic states and riboflavin deficiency. Lancet i: 12-143, 1978.
9. Rivlin RS. Riboflavin. In: Ziegler EE, Filer LJ Jr, eds. Present knowledge in nutrition. 7th edn. Washington DC: International Life Sciences Press. p 167-173, 1996.
10. Salim-Hanna M, Edwards AM, Silva E. A photo-induced adduct between a vitamin and an essential amino acid: binding of riboflavin to tryptophan. Int J Vit Nutr Res 57: 155-159, 1987.
11. Schoenen J, Jacquay J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology 50: 466-470, 1998.
12. Schoenen J, Lenaerts M, Bastings E. High-dosc riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia 14: 328-329, 1994.
13. Skalka HW, Prchal JT. Cataracts and riboflavin deficiency. Am J Clin Nutr 34: 861-863, 1981.
14. Webster RP, Gawde MD, Bhattacharya RK. Modulation of carcinogen-induced DNA damage and repair enzyme activity by dietary riboflavin. Cancer Lett 98: 129-135, 1996.
15. Weisburger J. Nutritional approach to cancer prevention with emphasis on vitamins, antioxidants, and cartenoids. Am J Clin Nutr 53: S226-227, 1991.

 

Sources
Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.

Vitamin B3, Research references

Admin

January 1999

1. Alhadeff L, Gualtieri GT, Lipton M. Toxic effects of water-soluble vitamins. Nutr Rev 42: 33-40, 1984.
2. Bendich A, Cohen M. Nutrition and immunology. New York: Alan R. Liss. p 114-115, 1988.
3. Carlson LA, Hamsten A, and Asplund A. Pronounced Lowering of Serum Levels of Lipoprotein Lp(a) in Hyperlipidaemic Subjects Treated with Nicotinic Acid, J Intern Med 226, 271-6, 1989.
4. Cheraskin E, Ringsdorf WM Jr, Medford FH. The ‘ideal’ daily niacin intake. Int J Vit Nutr Res 46: 58-60, 1976.
5. Cleary JP. Vitamin B3 in the Treatment of Diabetes Mellitus: Case Reports and Review of the Literature. J Nutr Med 1: 217-25, 1990.
6. DiPalma JR and Thayer WS, Use of Niacin as a Drug, Ann Rev Nutr 11; 169-87, 1991.
7. Einstein N, Baker A, Galper J et al. Jaundice due to nicotinic acid therapy. Am J Digest Dis 20: 282-286, 1975.
8. El-Enein AMA et al., The Role of Nicotinic Acid and Inositol Hexaniacinate as Anticholesterolemic and Antilipemic Agents, Nutr Rep Intl 28, 899-911, 1983.
9. Figge HL, Figge J, Souney PF et al. Nicotinic acid. A review of its clinical use in the treatment of lipid disorders. Pharmacotherapy 8: 287-294, 1988.
10. Gaby SK. Vitamin intake and health: A scientific review. New York: Marcel Dekker. p 189-192, 1991.
11. Goldsmith GA, Miller ON, Unglaub WG. Efficiency of tryptophan as a niacin precursor in man. J Nutr 73: 172-176, 1961.
12. Grundy SM. Drug therapy in dyslipidemia. Scand J Clin Lab Invest 50: 63-72, 1990.
13. Illingworth DR et al., Comparative Effects of Lovastatin and Niacin in Primary Hypercholesterolemia, Arch Intern Med 154, 1586-95, 1994.
14. Jacob, RA, Swendseid, ME. Niacin. In: Present knowledge in nutrition. 7th edn. Washington DC: International Life Sciences Press. p 184-190, 1996.
15. Jonas WB et al. The effect of niacinamide on osteoarthritis: a pilot study. Inflamm Res 45: 330-4, 1996.
16. Lefavi R. Lipid-lowering effects of a dietary nicotinic acid-chromium III complex in male athletes. FASEB J 5;6:A1645, 1991.
17. Lefavi R et al. Lipid-lowering effect of a dietary chromium III-nicotinic acid complex in male athletes. Nutr Res 13:239-49, 1993.
18. Luria MH. Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high density lipoprotein cholesterol ratio. Arch Intern Med 148: 2493-5, 1988.
19. Mandrup Paulsen T. Nicitinamide in the Prevention of Insulin Dependent Diabetes Mellitus. Diabetes Metabol Rev 9: 295-309, 1993.
20. McKenney JM et al., A Comparison of the Efficacy and Toxic Effects of Sustained- vs Immediate-Release Niacin in Hypercholesterolemic Patients, JAMA 271, 672-7, 1994.
21. O’Hara J, Jolly PN, Nicol CG. The therapeutic efficacy of inositol nicotinate (I lexopal) in intermittent claudication of a controlled trial. Br J Clin Practice 42: 377-383, 1988.
22. Patterson JI, Brown RR, Lindswiler H et al. Exertion of tryptophan-niacin metabolites by young men. Effects of tryptophan, leucine, and vitamin B6 intakes. Am J Clin Nutr 33: 2157-2167, 1980.
23. Pocoit F, Reimers JI and Andersen HU. Nicotinamide: Biological Actions and Therapeutic Potential in Diabetes Prevention. Diabetologia 36: 574-76, 1993.
24. Pozzilli P et al. The Potential Role of Nicotinamide in the Secondary Prevention of IDDM. Diabetes Metabol Rev 9: 219-30, 1993.
25. Salem and Abdel M. The Role of Nicotinic Acid and Inositol Hexaniacinate as Anticholesterolemic and Antilipemic Agents. Nutr Rep Intl 28: 899-911, 1983.
26. Urberg M and Zemel MB. Evidence for Synergism Between Chromium and Nicotinic Acid in the Control of Glucose Tolerance in Elderly Humans. Metabolism 36: 896-99, 1987.
27. Urberg M et al. Hypocholesterolemic effect of nicotinic acid and chromium supplementation. J Fam Pract 27;6:603-6, 1988.
28. Vega GL and Crundy SM. Lipoprotein Responses to Treatment with Lovastatin, Gemfibrozil, and Nicotinic Acid in Normolipidemic Patients with Hypoalphalipoproteinemia, Arch Intern Med 154: 73-82, 1994.
29. Welsh AL and Ede M, Inositol Hexanicotinate for Improved Nicotinic Acid Therapy, Int Record Med 174: 9-15, 1961.

 

Sources
Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.

Vitamin B5, Research references

Admin

January 1999

1. Barton-Wright EC, Elliott WA. The Pantothenic Acid Metabolism of Rheumatoid Arthritis. Lancet ii: 862-3, 1963.
2. Fry PC et al. Metabolic response to a pantothenic acid deficient diet in humans. J Nutr Sci Vitaminol 22: 339-46, 1976.
3. Welsh AL. Lupus erythematosus: Treatment by combined use of massive amounts of pantothenic acid and vitamin E. Arch Dermatol Syphilol 70: 181-98, 1954.


Sources
Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.

Vitamin B6, Research references

Admin

January 1999

1. Annand JC. Pyridoxine and magnesium in the treatment of shock. Lancet ii: 340-1, 1957.
2. Antopol W, Schotland CE. The use of vitamin B6 in pseudohypertrophic muscular dystrophy. JAMA, March 23, pp. 1058-9, 1940.
3. Barr W, Pyridoxine Supplements in the Premenstrual Syndrome, Practitioner 228: 425-7, 1984.
4. Bassler KH. Megavitamin therapy with pyridoxine. Int J Vit Nutr Res 58: 105-118, 1988.
5. Berman MK, et al. Vitamin B6 in Premenstrual Syndrom, J Am Diet Assoc 90 : 859-61, 1990.
6. Brattström L et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 81:1:51-60, 1990.
7. Brattström L, Stavenow L, Galvard H, et al. Pyridoxine reduces cholesterol and low-density-lipoprotein and increases antithrombin III activity in 80- year-old men with low plasma pyridoxal 5-phosphate. Scand J Clin Lab Invest 50:8:873-7, 1990.
8. Bum MK et al. Association of Vitamin B6 Status with Parameters of Immune Function in Early HIV-1 Infection. J AIDS 4:122-32, 1991.
9. Caby SK. Vitamin intake and health: A scientific review. New York: Marcel Dekker. p 163- 74, 1991.
10. Cohen M, Bendich A. Safety of pyridoxine – a review of human and animal studies. Toxicol Letters 34: 129-139, 1986.
11. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of the intake of vitamins C and B6, and the risk of kidney stones in men. J Urol 155:61847-51, 1996.
12. Dalery K et al. Homocysteine and coronary artery disease in French Canadian subjects: Relation with vitamins B12, B6, pyridoxal phosphate and folate. Am J Cardiol 75:1107-11, 1995.
13. Driskell JA, Wesley RL, Hess IE. Effectiveness of pyridoxine hydrochloride treatment on carpal tunnel syndrome patients. Nutr Rep Int 1986; 34: 103-1040, 1986.
14. Ellis JM. Vitamin B6 deficiency and rheumatism. Anabolism Winter 1985.
15. Folkers K, Morita M, McRee Jr. J. The activities of coenzyme Q10 and vitamin B6 for immune response. Biochem Biophys Res Commun 193:88-92, 1993.
16. Gaby AR. The safe use of vitamin B6 J Nutr Med 1: 153-157, 1990.
17. Gershoff SN, Prien EL. Excretion of urinary metabolites in calcium oxalate urolithiasis: Effect of tryptophan and vitamin B6 administration. Am J Clin Nutr 8:812, 1960.
18. Gershoff S, Prien EL. Effect of daily MgO and vitamin B6 administration to patients with recurring calcium oxalate kidney stones. Am J Clin Nutr 20:393-399, 1967.
19. Gibbs DA, Watts RWE. The action of pyridoxine in primary hyperoxaluria. Clin.Sci 38:277-86, 1970.
20. Gvozdova LG, Paramonova EG, Goriachenkova EV et al. The content of pyridoxal coenzymes in the blood plasma of patients with coronary atherosclerosis on a background of therapeutic diet and after supplemental intake of vitamin B6. Vop Pitan 25: 40-44, 1966.
21. Hallert C, Astrom J, Walan A. Reversal of psychopathology in adult coeliac disease with the aid of pyridoxine (vitamin B6). Scand J Gastroenterol 18; (2):299-304, 1983.
22. Harrison AR et al. Hyperoxaluria and recurrent stone formation apparently cured by short course of pyridoxine. Br Med J 282: 2097-8, 1981.
23. Jaeger P. et al. Idiopathic hyperoxaluria cured by a short course of pyridoxine B6: Further evidence for B6-deficiency. Abstract. Clin Res 34, 2:546A, 1962.
24. Jones CL et al. Pyridoxine Deficiency: A New Factor in Diabetic Neuropathy. J Am Pod Assoc 68: 646-53, 1978.
25. Kasidas GP et al. Mild but clinically significant metabolic hyperoxaluria and its response to pyridoxine, in H von G Gasser, Wahlensieck W, Eds. Pathogenese und Klinik Harnstein XI. Darmstadt, Steinkopff Verlag, 394-9, 1985.
26. Kok FJ et al. Low vitamin B6 status in patients with acute myocardial infarction. Am J Cardiol 63:513-16, 1989.
27. Kuzuya F. Arteriosclerosis in pyridoxine deficient-monkeys. Primates 2:99, 1959.
28. Kuzuya F F. Experiment on arteriosclerosis and arteriolosclerosis induced in pyridoxine-deficient monkeys and their recovery. Primates 3:77, 1962.
29. Kuzuya F. Reversibility of arteriosclerosis in pyridoxine-deficient monkeys, in G Schettler, Y Goto, Y Hata, G Klose, Eds. Atherosclerosis IV. Berlin, Springer-Verlag, 275-8, 1977.
30. Kuzuya F. Vitamin B6 and arteriosclerosis. Nagoya J Med Sci 55:1-4:1-9, 1993.
31. Lam SC et al. Investigation of possible mechanisms of pyridoxal-5-phosphate inhibition of platelet reactions. Thrombosis Res 20:633-45, 1980.
32. Leklem, JE. Vitamin B-6. In: Present knowledge in nutrition.7th edn. Washington DC: International Life Sciences Press. p 174-83, 1996.
33. Levene CI, Murray JC. The aetiological role of maternal B6 deficiency in the development of atherosclerosis. Lancet i:628, 1977.
34. Lewy A, Fox N. Clinical notes; New instruments and technics: Pyridoxine (B6) used in the treatment of vertigo. Arch Otolaryngol pp.681-3, Nov. 1947.
35. Lyon E, Borden T, Ellis J, Vermeulen C. Calcium oxalate lithiasis produced by pyridoxine deficiency and inhibition with high magnesium diets. Invest Urol 4: 133-142, 1966.
36. McCully KS. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 56: 111-128, 1969.
37. Milliner D, Eickholt J, Berstrahl E, et al. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med 331; 23:1553-8, 1994.
38. Mitwalli A et al. Control of hyperoxaluria with large doses of pyridoxine in patients with kidney stones. Int Urol Nephrol 20; 4:353-9, 1988.
39. Murthy MS, Farooqui S, Talwar HS, et al. Effect of pyridoxine supplementation on recurrent stone formers. Int J Clin Pharmacol Ther Toxicol 20; 9: 434-7, 1982.
40. Mushett CW, Emerson G. Arteriosclerosis in pyridoxine-deficient monkeys and dogs. Fed Proc 4:526-7, 1956.
41. Parry GJ, Bredesen DE. Sensory neuropathy with low dose pyridoxine. Neurology 1985; 35: 1466- 1468.
42. Prien EL, Gershoff S. Magnesium oxide-pyridoxine therapy for recurring calcium oxalate urinary calculi. J Urol 112:509-512, 1974.
43. Rattan VF, Sidhu H, Vaidyanathan S, et al. Effect of combined supplementation of magnesium oxide and pyridoxine in calcium-oxalate stone formers. Urol Res 22; 3:161-5, 1994.
44. Reinken L, Zieglauer H. Vitamin B6 absorption in children with acute celiac disease and in control subjects. J Nutr 108:1562, 1978.
45. Revusova V et al. The significance of oxaluria reduction by pyridoxine in prevention of calcium oxalate nephrolithiasis. Cas Lek Ces 121; 6:163-6, 1982.
46. Rinehart JF, Greenberg LD. Arteriosclerotic lesions in pyridoxine deficient monkeys. Am J Pathol 25:481-96, 1949.
47. Rinehart JF, Greenberg LD. Pathogenesis of experimental arteriosclerosis in pyridoxine deficiency with notes on similarities to human arteriosclerosis. Arch Pathol 51:12-29, 1951.
48. Rinehart JF, Greenberg LD. Vitamin B6 deficiency in the Rhesus monkey. Am J Clin Nutr 4:318-325, 1956.
49. Rhinehart JF, Greenberg LD. Vitamin B6 deficiency in the rhesus monkey, with particular reference to the occurrence of atherosclerosis, dental caries and hepatic cirrhosis. Am J Clin Nutr 4:318, 1956.
50. Roubenoff R et al. Abnormal vitamin B6 status in rheumatoid cachexia. Arthritis Rheum 1: 105-9, 1995.
51. Serofontein WJ, Ubbink JB, De Villiers LS, et al. Plasma pyridoxal-5-phosphate level as risk index for coronary artery disease. Atherosclerosis 55:3:357-61, 1985.
52. Serofontein WJ, Ubbink JB, De Villers LS, Becker PJ. Depressed plasma pyridoxal-5′-phosphate levels in tobacco-smoking men. Atherosclerosis. 59: 341-346; 1986.
53. Shor-Posner G, Feaster D, Blaney N, et al. Impact of Vitamin B6 Status on Psychological Distress in a longitudinal Study of HIV-1 infection. Int J Psychol Med 24; (3):209-22, 1994.
54. Shultz TD, Santamaria AG, Gridley DS et al. Effect of pyridoxine and pyridoxal on the in vitro growth of human malignant melanoma. Nutr Res 8: 201-207, 1988.
55. Solomon LR et al. Erythrocyte O2 Transport and Metabolism and Effects of Vitamin B6 Therapy in Type II Diabetes mellitus. Diabetes 38: 881-86, 1989.
56. Stone S. Pyridoxine and thiamine therapy in disorders of the nervous system. Dis Nerv Sys 11;5:131-8, 1950.
57. Subbarao K et al. Pyridoxal 5’-phosphate – a new physiological inhibitor of blood coagulation and platelet function. Biochem Pharmacol 28:531-4, 1979.
58. Swift ME, Shultz TD. Relationship of vitamins B6 and Bl2 to homocysteine levels: Risk for coronary heart disease. Nutr Rep Int 34: 1-14, 1986.
59. Talbott MC, Miller LT, Kerkvliet NI. Pyridoxine supplementation effect on Lymphocyte responses in elderly persons. Am J Clin Nutr 46: 659-664, 1987.
60. Thind SK et al. Role of vitamin B6 in oxalate metabolism in urolithiasis. Abstract. Am J Clin Nutr 32; 6:20, 1979.
61. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 57:47-53, 1993.
62. Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk of myocardial infarction: Relation with vitamin B6, B12, and folate. Am J Epidemiol 143:9:845-59, 1996.
63. Verrmaak WJ, Barnard HC, Potgieter GM et al. Plasma pyridoxal 5′-phosphate levels in myocardial infarction. S Afr Med J 70: 195-196, 1986.
64. Vermaak WJH et al. Vitamin B6 and coronary heart disease. Epidemiological observations and case studies. Atherosclerosis 63:235, 1987.
65. Vijayammal PL, Kurup PA. Pyridoxine and atherosclerosis: Role of pyridoxine in the metabolism of lipids and glycosaminoglycans in rats fed normal and high fat, high cholesterol diets containing 16% casein. Austral J Biol Sci 31:1:7-20, 1978.
66. Weisburger J. Nutritional approach to cancer prevention with emphasis on vitamins, antioxidant, and carotenoids. Am J Clin Nutr 53: S226-S237, 1991.

 

Sources
Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.